过去几年中,PD-1抑制剂如pembrolizumab(帕博利珠单抗)和nivolumab(纳武利尤单抗)及PD-L1抑制剂atezolizumab(阿特珠单抗)已获批用于多种适应症,如黑色素瘤、NSCLC等。. This evidence concerns the gene CD274 and non-small cell lung carcinoma.